Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Compare index fund performance year by year to detect stability, volatility, and opportunities for strategic adjustments.
25,004 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Exxon Mobil topped expectations in Q1 as LNG and Guyana projects accelerate. Investors are eyeing exxon mobil’s next ...
Upshift launches a new vault platform to deliver instant liquidity for real-world asset redemptions, backed by dedica...
SpaceX’s S-1 filing puts Elon Musk’s Mars ambitions under the public lens, inviting investors to weigh a multi-billio...
Two tech giants with very different engines share one common goal: sustainable growth. This analysis breaks down how ...
A rapid 16% drop in AGQ sent shockwaves through leveraged-silver traders as the underlying metal faced a harsh repric...
Bland, a San Francisco voice AI startup, raised $50 million in a Series C led by Dell Technologies Capital, defying d...
OpenAI's planned IPO faces a timing change that could redefine AI stock bets. The shift underscores a tougher funding...
EasyJet reaches a takeover price with a U.S. investor, valuing the airline at about £2.6 billion, but traders doubt t...
Box and DocuSign sit at different corners of the SaaS world. This analysis shows how quarterly revenue patterns illum...
Traditional finance offerings are bundling crypto yields into regulated products, but access is restricted by gatekee...
A top institutional SOL holder remains committed despite a near-$1 billion unrealized loss, shaping a long-term Solan...